Arlington, VA 的 乳癌 臨床試驗
47 項針對 乳癌 的研究正在 Arlington（約 30 英里範圍內）及其周邊地點尋找參與者。開啟研究以查看參與資格及聯絡研究團隊的方式。
官方研究文本（英文）
正在為研究招募對象嗎？將此頁面置頂展示 — $99 / 30 天 →
The Vanguard Study: Testing a New Way to Screen for Cancer
招募中歡迎健康志工
- Inova Schar Cancer Institute, Fairfax · 距離 11 英里
- Inova Fair Oaks Hospital, Fairfax · 距離 11 英里
Phase 3 Study of RLY-2608 + Fulvestrant vs Capivasertib + Fulvestrant as Treatment for Locally Advanced or Metastatic PIK3CA-mutant HR+/HER2- Breast Cancer
招募中3 期
- Virginia Cancer Specialists, PC, Fairfax · 距離 11 英里
A Study of PHST001 in Advanced Solid Tumors
招募中1 期
- NEXT Oncology - Virginia, Fairfax · 距離 11 英里
The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE)
招募中1/2 期
- Virginia Cancer Specialists, Fairfax · 距離 11 英里
A Phase 2 Neoadjuvant Study of Zanidatamab in Combination With Chemotherapy in Participants With HER2-positive Breast Cancer
招募中2 期
- Virginia Cancer Specialists, Fairfax · 距離 11 英里
Beamion BCGC-1: A Study to Find a Suitable Dose of Zongertinib Used Alone and in Combination With Other Treatments to Test Whether it Helps People With Different Types of HER2+ Cancer That Has Spread
招募中1/2 期
- Inova Schar Cancer Institute, Fairfax · 距離 11 英里
- Virginia Cancer Specialists, PC, Fairfax · 距離 11 英里
Phase II Protocol of Proton Therapy for Partial Breast Irradiation in Early Stage Breast Cancer
招募中2 期
- Inova Schar Cancer Institute, Fairfax · 距離 11 英里
Conventionally Fractionated vs. Hypofractionated Comprehensive Nodal Irradiation for Breast Cancer Using Pencil Beam Scanning Proton Therapy
招募中3 期
- Inova Schar Cancer Institute, Fairfax · 距離 11 英里
Study of AVZO-021 in Patients With Advanced Solid Tumors
招募中1/2 期
- Avenzo Therapeutics Recruiting Site, Fairfax · 距離 11 英里
A Study of Sacituzumab Tirumotecan (MK-2870) as a Single Agent and in Combination With Pembrolizumab (MK-3475) Versus Treatment of Physician's Choice in Participants With HR+/HER2- Unresectable Locally Advanced or Metastatic Breast Cancer (MK-2870-010)
招募中3 期
- Inova Schar Cancer Institute ( Site 0025), Fairfax · 距離 11 英里
A Phase III Study of Dato-DXd With or Without Durvalumab Compared With Investigator's Choice of Chemotherapy in Combination With Pembrolizumab in Patients With PD-L1 Positive Locally Recurrent Inoperable or Metastatic Triple-negative Breast Cancer (TROPION-Breast05)
招募中3 期
- Research Site, Fairfax · 距離 11 英里
ASPEN-09-03: A Study of Evorpacept in Combination With Trastuzumab and Chemotherapy in Metastatic HER2-Positive Breast Cancer
招募中2 期
- Virginia Cancer Specialists, Fairfax · 距離 11 英里
Signatera-Guided CDK4/6 Inhibitor Therapy in Breast Cancer
招募中
- Inova, Fairfax · 距離 11 英里
A Study of Tersolisib (LY4064809/STX-478) With Other Anti-Cancer Treatments in Participants With Advanced Breast Cancer With a Genetic Change (PIK3CA)
招募中3 期
- Virginia Cancer Specialists, Fairfax · 距離 11 英里
A Study of Imlunestrant (LY3484356) in Premenopausal Women With Estrogen Receptor-Positive (ER+) Human Epidermal Growth Factor Receptor 2 Negative (HER2-) Early Breast Cancer
招募中2 期
- Inova Schar Cancer Institute, Fairfax · 距離 11 英里
A Study of JNJ-101684362 (HLD-0117) in Patients With Metastatic Breast Cancer
招募中1 期
- Next Virginia, Fairfax · 距離 11 英里
A Phase 1/2 Trial of TER-2013 in Patients With Solid Tumors Harboring AKT/PI3K/PTEN Pathway Alterations
招募中1/2 期
- NEXT Oncology, Fairfax · 距離 11 英里
A Study of Elacestrant Versus Standard Endocrine Therapy in Women and Men With ER+,HER2-, Early Breast Cancer With High Risk of Recurrence
招募中3 期
- Inova Schar Cancer Institute, Fairfax · 距離 11 英里
- Virginia Cancer Specialists, Fairfax · 距離 11 英里
Open Label Study to Evaluate BL-M07D1 in HER2 Expressing Malignant Solid Tumors
招募中1 期
- Virginia Cancer Specialists, Fairfax · 距離 11 英里
A Phase 1/1b Study of IAM1363 in HER2 Cancers
招募中1 期
- NEXT Oncology - Virginia Cancer Specialists, Fairfax · 距離 11 英里
A Study to Evaluate Safety, Tolerability and Preliminary Activity of AGX101 in Participants With Advanced Solid Tumors
招募中1 期
- NEXT Oncology, Fairfax · 距離 11 英里
Study of ORIC-114 in Patients With Advanced Solid Tumors Harboring an EGFR or HER2 Alteration
招募中1/2 期
- Next Oncology, Fairfax · 距離 11 英里
Study of AMXT 1501 and DFMO in Combination With Standard Therapies in Advanced Solid Tumors
招募中1/2 期
- Virginia Cancer Specialists-Fairfax, Fairfax · 距離 11 英里
A Study of ASP2998 Given by Itself and Given With Standard Therapies in People With Solid Tumors
招募中1/2 期
- NEXT Virginia, Fairfax · 距離 11 英里
Evaluating the Addition of Adjuvant Chemotherapy to Ovarian Function Suppression Plus Endocrine Therapy in Premenopausal Patients With pN0-1, ER-Positive/HER2-Negative Breast Cancer and an Oncotype Recurrence Score Less Than or Equal to 25
招募中3 期
- Kaiser Permanente Tysons Corner Medical Center, McLean · 距離 5 英里
- Kaiser Permanente-Burke Medical Center, Burke · 距離 11 英里
A Study With NKT5097 for Adults With Advanced/Metastatic Solid Tumors
招募中1 期
- NEXT Virginia, Fairfax · 距離 11 英里
A Study of Mutant Selective-Inhibitor (CGT6297), in Patients With Advanced Solid Tumors
招募中1 期
- NEXT Virginia, Fairfax · 距離 11 英里
A Phase 1 Study of LNCB74 in Advanced Solid Tumors
招募中1 期
- Inova Schar Cancer Institute, Falls Church · 距離 4 英里
Testing Proton Craniospinal Radiation Therapy Versus the Usual Radiation Therapy for Leptomeningeal Metastasis, RADIATE-LM Trial
招募中3 期
- Inova Schar Cancer Institute, Fairfax · 距離 11 英里
- Inova Fair Oaks Hospital, Fairfax · 距離 11 英里
Phase 3 Study to Evaluate the Efficacy and Safety of HER2/Neu Peptide GLSI-100 (GP2 + GM-CSF) in HER2/Neu Positive Subjects
招募中3 期
- Virginia Cancer Specialists, Fairfax · 距離 11 英里
E-Mindfulness Approaches for Living After Breast Cancer
招募中3 期
- Inova Fairfax Hospital, Falls Church · 距離 4 英里
- Kaiser Permanente Tysons Corner Medical Center, McLean · 距離 5 英里
- Inova Schar Cancer Institute, Fairfax · 距離 11 英里
- 還有 1 項
Rinatabart Sesutecan (Rina-S, PRO1184, GEN1184) for Advanced Solid Tumors (GCT1184-01/ PRO1184-001)
招募中1/2 期
- USOR Virginia Cancer Specialists, Fairfax · 距離 11 英里
Study of RGT-490 in Patients With PIK3CA-Mutated Advanced Solid Tumors
招募中1 期
- NEXT Virginia, Fairfax · 距離 11 英里
First-in-Human Study of Tersolisib (STX-478) as Monotherapy and in Combination With Other Antineoplastic Agents in Participants With Advanced Solid Tumors
招募中1/2 期
- USO-Virginia Cancer Specialists, PC, Fairfax · 距離 11 英里
Pre-Operative Window of ET to Inform RT Decisions (POWER II)
招募中3 期
- INOVA Schar Cancer, Fairfax · 距離 11 英里
A Study of Emiltatug Ledadotin (Emi-Le) in Participants With Solid Tumors
招募中1/2 期
- NEXT Oncology Virginia, Fairfax · 距離 11 英里
Phase 1/2 Study of ETX-636 in Participants With Advanced Solid Tumors
招募中1/2 期
- NEXT, Fairfax · 距離 11 英里
Phase 1/2 Study to Evaluate EP0062 as Monotherapy and in Combination in Patients With Advanced or Metastatic AR+/HER-2-/ER+ Breast Cancer
招募中1/2 期
- Virginia Cancer Specialists, Fairfax · 距離 11 英里
Study of Patritumab Deruxtecan With Other Anticancer Agents in Participants With HER2 Positive Breast Cancer That Has Spread and Cannot Be Surgically Removed (MK-1022-009)
招募中1/2 期
- Inova Schar Cancer Institute ( Site 0051), Fairfax · 距離 11 英里
A Study to Learn About the Study Medicine Called PF-07248144 in Combination With Fulvestrant in People With HR-positive, HER2-negative Advanced or Metastatic Breast Cancer Who Progressed After a Prior Line of Treatment.
招募中3 期
- Virginia Cancer Specialists, PC, Reston · 距離 14 英里
- Virginia Cancer Specialists, Manassas · 距離 22 英里
A Study to Evaluate the Safety and Tolerability of TOS-358 in Women With HR+ HER2- Breast Cancer
招募中1 期
- Virginia Cancer Specialists, Fairfax · 距離 11 英里
Phase I Study of SYS6043 in Patients With Advanced/Metastatic Solid Tumors
招募中1 期
- NEXT Oncology Virginia, Fairfax · 距離 11 英里
A Study of DB-1310 in Advanced/Metastatic Solid Tumors
招募中1/2 期
- NEXT Virginia, Fairfax · 距離 11 英里
A Study of PARG Inhibitor ETX-19477 in Patients With Advanced Solid Malignancies
招募中1/2 期
- Virginia Cancer Specialists, Fairfax · 距離 11 英里
Phase 1/2 Dose Finding, Safety and PK Study in Advanced Refractory Solid Tumors
招募中1/2 期
- NEXT, Virginia, Fairfax · 距離 11 英里
First-in-Human Study of Mutant-selective PI3Kα Inhibitor, RLY-2608, as a Single Agent in Patients With Advanced Solid Tumors and in Combination With Endocrine Therapy +/- a CDK4/6 or CDK4 Inhibitor in Patients With Advanced Solid Tumors or Advanced Breast Cancer
招募中1 期
- Inova Schar Cancer Center, Fairfax · 距離 11 英里
- NEXT Virginia, Fairfax · 距離 11 英里
Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of BTX-9341 in Advanced and/or Metastatic Breast Cancer
招募中1 期
- Biotheryx Investigative Site, Fairfax · 距離 11 英里
其他城市的 乳癌 試驗
- New York City, NY136 項研究
- Houston, TX126 項研究
- Boston, MA112 項研究
- Nashville, TN81 項研究
- Los Angeles, CA73 項研究
- Edison, NJ68 項研究
- St. Louis, MO64 項研究
- Queens, NY64 項研究
- Durham, NC64 項研究
- Chicago, IL59 項研究
- Philadelphia, PA56 項研究
- Dallas, TX55 項研究
Arlington 的其他研究
- 非小細胞肺癌104 項研究
- 轉移性癌症53 項研究
- 大腸直腸癌52 項研究
- 癌症（所有類型）48 項研究
- 卵巢癌46 項研究
- 肺癌41 項研究
- 子宮內膜癌39 項研究
- 胰臟癌33 項研究
- 頭頸部鱗狀細胞癌26 項研究
- 小細胞肺癌23 項研究
- 胃癌20 項研究
- 三陰性乳癌20 項研究
資料來源：ClinicalTrials.gov，擷取日期 2026年10月6日。各研究自行設定資格標準；由研究團隊決定參與者資格。